New hope for stomach and bowel cancers? phase 2 trial launches
NCT ID NCT07539311
First seen Apr 28, 2026 · Last updated May 22, 2026 · Updated 6 times
Summary
This study tests a new drug called rinatabart sesutecan (Rina-S) in about 160 people with advanced gastrointestinal cancers that have spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors or slow cancer growth. All participants receive the active drug, and the study lasts about 22 months on average.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.